TABLE 4.
Determination of restricting HLA allele of lesion-derived CD4 TCC 4.2E1 and 2.3a
| TCC | Antigen | APC | HLA typeb | Δcpmc |
|---|---|---|---|---|
| 4.2E1 | 1.1.3 | Autologous EBV-LCL | DPB1*0402, 2001 | 30,719 |
| AMAI EBV-LCL | DPB1*0402 | 2,732 | ||
| ARENT EBV-LCL | DPB1*2001 | 26,218 | ||
| 2.3 | 50.583.44 | Autologous PBMC | DRB1*0301, 0701 | 8,964 |
| Allogeneic PBMC A | DRB1*0701, 1001 | 45 | ||
| Allogeneic PBMC B | DRB1*0301, 1301 | 19,223 |
a
Antigens were β-galactosidase fusion proteins (Table 2) at a 1:900 deletion.
b
HLA type at the HLA class II locus as determined by inhibition with MAb (data not shown).
c
In comparison to pUEX2 control protein (1:1,000 dilution) with the same APC, which caused less than 500 cpm of [3H]thymidine incorporation in each case.